Key Points
- Director Katie Peng sold 1,006 shares on December 16 at an average price of $44.09 for a total of $44,354.54, leaving her with 32,908 shares (a 2.97% reduction) valued at about $1.45 million.
- Scholar Rock shares opened at $42.93 with a market cap of $4.38 billion and a 52‑week range of $22.71–$48.28; the company reported Q3 EPS of -$0.90 versus consensus -$0.88 and analysts forecast about -2.42 EPS for the year.
- Institutional investors own 91.08% of the stock with major increases by Vanguard and Wellington, and analysts show a consensus Buy rating with an average target price of $48.92.
Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) Director Katie Peng sold 1,006 shares of the company's stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $44.09, for a total transaction of $44,354.54. Following the transaction, the director owned 32,908 shares of the company's stock, valued at approximately $1,450,913.72. This represents a 2.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Scholar Rock Stock Performance
Shares of NASDAQ SRRK opened at $42.93 on Friday. The company has a market cap of $4.38 billion, a P/E ratio of -13.63 and a beta of 0.61. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $48.28. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm's fifty day moving average is $36.36 and its two-hundred day moving average is $35.39.
Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.02). During the same quarter in the previous year, the firm posted ($0.66) earnings per share. As a group, analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Scholar Rock by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company's stock valued at $183,032,000 after acquiring an additional 53,333 shares during the period. Wellington Management Group LLP raised its position in Scholar Rock by 124.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company's stock worth $169,289,000 after purchasing an additional 2,521,022 shares during the period. Bellevue Group AG lifted its stake in Scholar Rock by 10.1% in the third quarter. Bellevue Group AG now owns 3,244,537 shares of the company's stock worth $120,827,000 after purchasing an additional 297,242 shares during the last quarter. Eventide Asset Management LLC boosted its position in shares of Scholar Rock by 9.5% during the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company's stock valued at $103,192,000 after buying an additional 251,638 shares during the period. Finally, Holocene Advisors LP bought a new position in shares of Scholar Rock during the third quarter valued at approximately $91,670,000. Institutional investors own 91.08% of the company's stock.
Analysts Set New Price Targets
SRRK has been the subject of several research analyst reports. Jefferies Financial Group began coverage on Scholar Rock in a report on Thursday, August 21st. They set a "buy" rating and a $50.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Scholar Rock in a report on Thursday, December 11th. Bank of America assumed coverage on shares of Scholar Rock in a research report on Thursday, October 9th. They issued a "buy" rating and a $53.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an "overweight" rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Scholar Rock in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Scholar Rock has a consensus rating of "Buy" and an average target price of $48.92.
Get Our Latest Report on Scholar Rock
About Scholar Rock
(
Get Free Report)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
